Nebenwirkungen · Actos
Actos 15 mg tablets Actos 30 mg tablets Actos 45 mg tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-091036 · Präparat HOS-084177
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to< 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-28T15:56:00Z · SHA-256 9db485a8edb528eab1b3fb65eee070f4e61e0143333341420cf15c5240029983 · Passage 912c871ea959c1d2c74e35e0e688c40534d03e5247bba73dcd065be89e4c5413 · Zeichen 37–630 im Abschnitt